Navigation Links
$10 Million Verdict Against Johnson & Johnson Unit for Toxic Motrin Reaction, Announces The Jensen Law Firm
Date:5/24/2011

PHILADELPHIA, May 24, 2011 /PRNewswire/ -- Members of Fort Worth, Texas-based Jensen Law Firm (www.stevensjohnsonsyndrome.org) are pleased to announce a $10 million verdict in compensatory damages against Johnson & Johnson's McNeil Consumer Products (NYSE: JNJ) unit on behalf of 13-year-old Brianna Maya and her family. Brianna suffered disfiguring, life-altering skin burns and permanent blindness after she was given Children's Motrin to treat a fever and cough in 2000. (Alicia E. Maya, et al. v. Johnson & Johnson, et al., Case No. 002879, Court of Common Pleas, Philadelphia County, Pennsylvania)

When Brianna was 3 years old, she was given Children's Motrin. Soon after, she developed a rash, skin lesions, eye infections, and lung damage. Her family didn't know at the time that Children's Motrin had been linked to Toxic Epidermal Necrolysis (TEN) and Stevens-Johnson Syndrome (SJS), severe allergic reactions that can cause patients' skin to burn off, leave patients blind and disfigured.  Now 13, Brianna continues to experience the effects of taking the drug, including:

  • blindness in one eye, corneal scarring in both eyes, and recurring eye infections
  • ongoing eye surgeries needed to maintain vision
  • permanent disfigurement to her face, eyelids, and body after 84 percent of her skin was burned when she initially took the medicine
  • permanent lung damage, including a 50 percent loss of lung capacity with recurring lung infections and pneumonia
  • brain damage and recurring seizures
  • internal and external scarring resulting in permanent loss of reproductive system

Jurors deliberated for approximately 10 hours before holding J&J's McNeil Consumer Products unit liable for Brianna's injuries and awarded her $10 million.   Her recoverable medical expenses were less than $2.5 million. The jury found that McNeil Consumer Products was negligent in failing to adequately warn about the risks of over-the-counter Children's Motrin and that this negligence was a cause of Brianna's injuries.

“Justice has been served,” said attorney Keith Jensen, founding partner of The Jensen Law Firm. “Drug companies must understand that if they fail to warn consumers about the known risks of their products, juries will hold them accountable.  How many parents would buy Children’s Motrin if they were told, as J&J and McNeil admitted at trial, that Children’s Tylenol was safer and more effective than Children’s Motrin and does not cause SJS, TEN or resultant blindness, disfigurement or lung damage?”

Members of The Jensen Law Firm have handled similar cases in the past. In September 2010, Jensen obtained a $21 million verdict against Mutual Pharmaceutical on behalf of a client who suffered from TEN stemming from taking a different NSAID (not Ibuprofen/Motrin but sulindac). This remains the largest jury verdict in New Hampshire history. (Karen L. Bartlett v. Mutual Pharmaceutical Company, Inc., Civil No. 08-358-JL, U.S. District Court, District of New Hampshire)

Johnson & Johnson is the world's second-largest seller of medical products and recalled more than 40 consumer brands last year—including children's versions of Tylenol, Motrin and St. Joseph Aspirin.

About The Jensen Law Firm

The Jensen Law Firm represents individuals and families in cases involving catastrophic personal injuries, death, or financial ruin resulting from the negligence or wrongdoing of drug manufacturers and others. To learn more, visit www.stevensjohnsonsyndrome.org.

For more information, contact:
Abbey Smith
Phone: 615-296-1078
Email: abbey@cjadvertising.com


'/>"/>
SOURCE The Jensen Law Firm
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
2. University Hospitals Seidman Cancer Center Announces $30 Million Proton Therapy Center
3. TechPrecision Corporation Receives $1.6 Million in New Orders from Existing Customers
4. Isis Earns $3 Million Payment as Collaboration With GSK Expands
5. Halozyme Therapeutics and ViroPharma Announce $83 Million Global Licensing Agreement to Develop Subcutaneous Cinryze® (C1 esterase inhibitor [human])
6. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
7. Vermillion Reports Financial Results for the First Quarter 2011
8. The Female Health Companys Brazilian Distributor, Semina, Awarded Contract For Up To 20 Million FC2 Female Condoms
9. HeartWare International Reports First Quarter 2011 Revenues of $18.0 Million; 68% Increase From $10.7 Million in First Quarter 2010
10. Spring Bank Pharmaceuticals Awarded $3.9 Million RO1 NIH Grant to Advance Innovative Hepatitis Program
11. Eli Lilly and Company Invests $2.5 Million to Launch The Mind Trusts Grow What Works Campaign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):